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HIGH-DOSE CEF (CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUORO-
URACIL) AS PRIMARY CHEMOTHERAPY IN LOCALLY ADVANCED
BREAST CANCER: LONG TERM SURVIVAL DATA
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Anza`, M. Della Giulia, M. Lopez. Regina Elena Institute for Cancer
Research, Rome, Italy
Purpose: To determine wether primary CEF is effective in
locally advanced breast cancer, as measured by response, local
recurrences, disease free survival (DFS) and overall survival (OS).
Patients and methods: From 1990 to 1998, 62 patients (pts) with
stage III disease were enroled into a prospective study at Regina
Elena Institute for Cancer Research, Rome. Inflammatory breast
cancer (IBC) was included. Pts received three 21 d cycles of che-
motherapy that consisted in epirubicin 50 mg/m2, cyclophospha-
mide 400 mg/m2 and fluorouracil 500 mg/m2 i.v. on days 1 and 8.
G-CSF (300 lg) was given subcutaneously every other day from
days 5 to 17. After primary chemotherapy, whenever possible,
mastectomy or conservative surgery was performed. Subse-
quently responding pts received the same regimen, whilst non-
responders were given a non-cross resistant chemotherapy. In
case of conservative surgery or initial T4 tumour radiation ther-
apy was performed at the end of adjuvant chemotherapy. ER posi-
tive pts received tamoxifen 20 mg/d for five years.
Results: Median follow for the cohort was 109 months (range,
10–199). The local recurrence rate was 19.3%; two pts developed
a new primary cancer in the contralateral breast. Distant metas-
tases occurred in 29 pts (46.7%). The 5 years DFS rate for IIIA pts
was 14.3% (median DFS: 27, CI 95% 17–37), for IIIB was 52.5%
(median DFS: 87, CI 95% 10–175) for IBC was 20% (median DFS:
27 month, CI 95% 14–40), p-value 0.009. The 10-years OS for the
IIIA pts was 28.6% (median OS: 43 month, CI 95% 30–56), for IIIB
was 47.5% (median OS:116 month, CI 95% 47–185) and for IBC
was 26.7% (median OS: 46 month, IC 26–66), p-value 0.11.
Conclusion: Ten years of follow up of stage III breast cancer is
rarely reported. In IIIB pts we obtained a good local control and
interesting long term data of OS.
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Background: DCIS currently accounts for up 25% of all newly
diagnosed breast cancers, but it can give rise to potentially lethal
invasive carcinoma if undetected and left untreated. We are
unable to predict which DCIS will progress to invasive cancer
and the time interval to the development of recurrent DCIS or
invasive carcinoma.
Methods: Retrospectively one hundred seventy patients (pts)
with DCIS of the breast were observed between 1996 and 2007
in our Institution. The main characteristics of these pts included:
median age 53 years (range 23–78); menopause 112 pts (66%); fer-
tility 139 pts (82%); surgery: mastectomy 39 pts (23%) and local
excision 131 pts (77%). After breast-conserving treatment (BCT)
123 pts (94%) received radiotherapy. Overall, 72 pts (42%) received
tamoxifen.
Results: With median follow-up of 56 months (range 4–71),
recurrence rate was 4.7% (8 pts: 5 ispilateral; 2 controlateral and
1 ipsilateral + controlateral synchronous). Median relapse free
survival was 45 months (21–87). Approximately 75% of the of
these recurrences have developed invasive cancer and 25% DCIS.
All pts had more than 40 years (6/8 between 40 and 50 years) and
underwent BCT. The initial histological characteristics of these
women were: 7/8 comedo carcinoma and 6/8 presence of disease
at the surgical margins. Seven of these pts underwent breast irra-
diation (87.5%) and only three pts (37.5%) hormonal therapy with
tamoxifen. The overall survival of all group was 95.3%.
Conclusions: These retrospective data confirmed that mastec-
tomy treatment is associated with optimal local control. Pts with
age between 40 and 50 years and comedocarcinoma histology
might be considered at high risk of local recurrence.
doi:10.1016/j.ejcsup.2008.06.030
NUOVO RUOLO DEGLI INIBITORI DELL’AROMATASI: IMPIEGO IN
TERAPIA ADIUVANTE
A. Molino. Oncologia Medica Clinicizzata, Universita` degli Studi di
Verona, Italy
Il trattamento ormonale ha l’obiettivo di impedire che gli
estrogeni possano legarsi ai recettori ormonali: requisito fonda-
mentale a tutti i tipi di manipolazione ormonale e` dunque
l’espressione da parte delle cellule tumorali dei recettori per gli
estrogeni e/o per il progesterone.
Le opzioni terapeutiche sono diverse: in premenopausa e` nec-
essario abolire l’attivita` ovarica con i farmaci agonisti LH-RH, che
portano alla soppressione della produzione di estrogeni mediante
interferenza con l’asse ipotalamo-ipofisi, con conseguente ipog-
onadismo di origine centrale (castrazione medica); a questi va
associato il tamoxifen, che compete con gli estrogeni prodotti in
sede extraovarica per il legame con i recettori.
In menopausa il tamoxifen era la terapia standard fino a qual-
che anno fa, ma negli ultimi anni e` stata sviluppata una nuova
categoria di farmaci, gli inibitori di terza generazione dell’enzima
aromatasi (anastrozolo, letrozolo, exemestane); l’aromatasi e`
l’enzima responsabile, in menopausa, della conversione degli
androgeni surrenalici in estrogeni: questa avviene a livello perife-
rico, cioe` osso, fegato, muscolo, tessuto adiposo, tessuto tumorale
mammario. Mentre il tamoxifen e` un farmaco ampiamente usato
da piu` di 30 anni e quindi ben conosciuto, gli effetti a lungo ter-
mine degli inibitori dell’aromatasi sono per certi versi ancora
non del tutto noti.
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